171 related articles for article (PubMed ID: 1829886)
21. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.
Kruithof EK; Tran-Thang C; Ransijn A; Bachmann F
Blood; 1984 Oct; 64(4):907-13. PubMed ID: 6434006
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of the inhibition by plasminogen activator inhibitor 2 of urokinase isolated from human urine and recombinant microorganisms. Further evidence for correct tertiary structure of recombinant urokinase.
Cramer J; Steffens G; Günzler WA; Hess V; Flohé L
Arzneimittelforschung; 1988 Aug; 38(8):1196-8. PubMed ID: 3143371
[TBL] [Abstract][Full Text] [Related]
23. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Stephens RW; Fordham CJ; Doe WF
Eur J Cancer Clin Oncol; 1987 Feb; 23(2):213-22. PubMed ID: 2965017
[TBL] [Abstract][Full Text] [Related]
24. [Interaction of plasminogen activator of urokinase type with human serum].
Vakulina OP; Popkova EV; Isachenkov VA
Vopr Med Khim; 1988; 34(4):32-6. PubMed ID: 3143185
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
26. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.
Edelberg JM; Weissler M; Pizzo SV
Biochem J; 1991 Jun; 276 ( Pt 3)(Pt 3):785-91. PubMed ID: 1829607
[TBL] [Abstract][Full Text] [Related]
27. Demonstration of plasminogen activator activity in the intima and media of the normal human aorta and other large arteries: immunological identification of the plasminogen activator(s).
Smokovitis AA; Kokolis NA; Alexaki E; Binder BR
Thromb Res; 1989 Jul; 55(2):259-65. PubMed ID: 2528844
[TBL] [Abstract][Full Text] [Related]
28. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin.
Osterwalder T; Cinelli P; Baici A; Pennella A; Krueger SR; Schrimpf SP; Meins M; Sonderegger P
J Biol Chem; 1998 Jan; 273(4):2312-21. PubMed ID: 9442076
[TBL] [Abstract][Full Text] [Related]
29. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
30. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
Félez J; Rueda F
Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
[No Abstract] [Full Text] [Related]
31. In vitro effects of urokinase--prevention by different inhibitors.
Oethinger MD; Seifried E
Thromb Haemost; 1990 Nov; 64(3):402-6. PubMed ID: 1710833
[TBL] [Abstract][Full Text] [Related]
32. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
[TBL] [Abstract][Full Text] [Related]
33. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor.
Lecander I; Roblin R; Astedt B
Br J Haematol; 1984 Jul; 57(3):407-12. PubMed ID: 6430331
[TBL] [Abstract][Full Text] [Related]
34. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
[TBL] [Abstract][Full Text] [Related]
35. Nordihydroguaiaretic acid inhibits urokinase synthesis by phorbol myristate acetate-stimulated LLC-PK1 cells.
Rondeau E; Guidet B; Lacave R; Bens M; Sraer J; Nagamine Y; Ardaillou R; Sraer JD
Biochim Biophys Acta; 1990 Nov; 1055(2):165-72. PubMed ID: 2122915
[TBL] [Abstract][Full Text] [Related]
36. Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes.
Berkenpas MB; Quigley JP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7768-72. PubMed ID: 1652763
[TBL] [Abstract][Full Text] [Related]
37. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
38. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
39. An inhibitor of plasminogen activator produced by tumour cell fusion hybrids.
Badenoch-Jones P; Ramshaw IA; Grant A
Aust J Exp Biol Med Sci; 1985 Jun; 63 ( Pt 3)():343-52. PubMed ID: 2933023
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of the plasminogen activator from HeLa cells by peptides of arginine chloromethyl ketone.
Coleman P; Kettner C; Shaw E
Biochim Biophys Acta; 1979 Jul; 569(1):41-51. PubMed ID: 111716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
